Manila Times Business
Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress
SHANGHAI, June 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, presented two latest clinical study results of its independently developed Nectin-4-targeting ADC 9MW2821 (Bulumtatug Fuvedotin, BFv) in cervical cancer at the European Society for Medical Oncology Gynaecological Cancers Congress 2026 (ESMO Gynae 2026) in Copenhagen, Denmark, held June 17-19, 2026. The two studies demonstrated that 9MW2821
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
LitigatorsAi Launches Court Safe Citation Validation to Catch Ai-Fabricated Case Law Before It Reaches a Judge
3h ago
Forefront Tech Holdings Acquisition Corp Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing June 22, 2026
3h ago
Lysander Funds Limited Announces Canso Credit Income Fund’s Intention to Utilize Repurchase and Reverse Repurchase Transactions
3h ago
XTB Group Consolidates B2B Operations as X Open Hub Transitions to XTB Institutional
3h ago